Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|
Net Debt | ($321.0M) | ($206.9M) | ($471.3M) | ($582.4M) | ($1,249.8M) | ($1,843.1M) | ($15.0B) | ($17.8B) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, BioNTech SE's last 12-month Net Debt is ($18.3B), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BioNTech SE's Net Debt growth was 10.1%. The average annual Net Debt growth rates for BioNTech SE have been 190.5% over the past three years, 105.1% over the past five years.
Over the last year, BioNTech SE's Net Debt growth was 10.1%, which is higher than industry growth of (0.1%). It indicates that BioNTech SE's Net Debt growth is Bad.